Penserra Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $229K | Buy |
1,057
+332
| +46% | +$73.6K | ﹤0.01% | 642 |
|
|
2025
Q4 | $165K | Sell |
725
-46
| -6% | -$10.5K | ﹤0.01% | 690 |
|
|
2025
Q3 | $177K | Sell |
771
-93
| -11% | -$18.9K | ﹤0.01% | 719 |
|
|
2025
Q2 | $159K | Buy |
864
+720
| +500% | +$134K | ﹤0.01% | 672 |
|
|
2025
Q1 | $30K | Sell |
144
-4,476
| -97% | -$870K | ﹤0.01% | 865 |
|
|
2024
Q4 | $820K | Buy |
4,620
+4,476
| +3,108% | +$823K | 0.02% | 464 |
|
|
2024
Q3 | $28K | Hold |
144
| – | – | ﹤0.01% | 859 |
|
|
2024
Q2 | $25K | Hold |
144
| – | – | ﹤0.01% | 905 |
|
|
2024
Q1 | $26K | Sell |
144
-8,025
| -98% | -$1.38M | ﹤0.01% | 900 |
|
|
2023
Q4 | $1.26M | Sell |
8,169
-2,339
| -22% | -$341K | 0.02% | 339 |
|
|
2023
Q3 | $1.56M | Sell |
10,508
-1,657
| -14% | -$243K | 0.03% | 287 |
|
|
2023
Q2 | $1.64M | Buy |
12,165
+11,309
| +1,321% | +$1.66M | 0.03% | 321 |
|
|
2023
Q1 | $136K | Sell |
856
-24,108
| -97% | -$3.69M | ﹤0.01% | 741 |
|
|
2022
Q4 | $4.03M | Buy |
24,964
+23,230
| +1,340% | +$3.56M | 0.09% | 159 |
|
|
2022
Q3 | $232K | Buy |
1,734
+1,446
| +502% | +$207K | 0.01% | 595 |
|
|
2022
Q2 | $44K | Sell |
288
-2,824
| -91% | -$432K | ﹤0.01% | 926 |
|
|
2022
Q1 | $503K | Sell |
3,112
-2,248
| -42% | -$327K | 0.01% | 496 |
|
|
2021
Q4 | $724K | Buy |
5,360
+4,966
| +1,260% | +$587K | 0.02% | 450 |
|
|
2021
Q3 | $41K | Buy |
394
+54
| +16% | +$6.17K | ﹤0.01% | 1102 |
|
|
2021
Q2 | $38K | Buy |
+340
| New | +$38.3K | ﹤0.01% | 1058 |
|
|
2020
Q3 | – | Sell |
-3,390
| Closed | -$332K | – | 927 |
|
|
2020
Q2 | $332K | Buy |
+3,390
| New | +$298K | 0.02% | 423 |
|
|
2019
Q1 | – | Sell |
-357
| Closed | -$32K | – | 712 |
|
|
2018
Q4 | $32K | Buy |
+357
| New | +$31.4K | ﹤0.01% | 516 |
|
|
2018
Q3 | – | Sell |
-17,455
| Closed | -$1.62M | – | 688 |
|
|
2018
Q2 | $1.62M | Buy |
17,455
+17,134
| +5,338% | +$1.67M | 0.1% | 172 |
|
|
2018
Q1 | $30K | Buy |
+321
| New | +$35.3K | ﹤0.01% | 459 |
|
|
2017
Q2 | – | Sell |
-2,162
| Closed | -$140K | – | 520 |
|
|
2017
Q1 | $140K | Buy |
2,162
+188
| +10% | +$11.8K | 0.01% | 268 |
|
|
2016
Q4 | $123K | Buy |
1,974
+210
| +12% | +$12.8K | 0.01% | 307 |
|
|
2016
Q3 | $111K | Buy |
1,764
+882
| +100% | +$57.1K | 0.01% | 260 |
|
|
2016
Q2 | $55K | Buy |
882
+294
| +50% | +$17.9K | 0.01% | 329 |
|
|
2016
Q1 | $33 | Buy |
588
+108
| +23% | +$6.02K | ﹤0.01% | 359 |
|
|
2015
Q4 | $28K | Buy |
+480
| New | +$27.6K | ﹤0.01% | 348 |
|
Other funds holding ABBV
VCM
VPM
Penserra Capital Management's ABBV Position: Q1 2026 in Review
Penserra Capital Management increased its AbbVie (ABBV) stake by 46% in Q1 2026, buying an estimated $73.6K and bringing the position to 1,057 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #642.
Penserra Capital Management first reported a position in ABBV in Q4 2015 and has held it in 30 quarters since. The position peaked at $4.03M in Q4 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Penserra Capital Management held 1,057 shares of AbbVie worth $229K as of Q1 2026.
- Penserra Capital Management bought 332 AbbVie shares in Q1 2026, an estimated $73.6K.
- AbbVie made up ﹤0.01% of Penserra Capital Management's portfolio in Q1 2026, its #642 holding.
- Penserra Capital Management first reported a position in AbbVie in Q4 2015 and has held it in 30 quarters since.
- Penserra Capital Management's AbbVie position peaked at $4.03M in Q4 2022.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.